At the best cutoff value (0.70 ng/mL), which maximized the sum of sensitivity and specificity by ROC analysis, ITGB4 could discriminate CRC patients from HCs with a sensitivity of 79.59% and specificity of 62.4% in part I, which included 49 CRC patients and 367 HCs (Figure 1B,C). Here, ITGB4 is linked to colorectal carcinoma.